Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04534699 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
A Phase 1 study, sponsored by KBP Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04534699 is a Phase 1 study that has completed, run by KBP Biosciences. The registered enrollment target is 12 participants.
The verdict
NCT04534699, a Phase 1 study, has completed, sponsored by KBP Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of KBP-5074.
Interventions
- DRUG KBP-5074
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-08-27 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04534699
The ClinicalTrials.gov registry entry for NCT04534699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KBP Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KBP-5074 is the first listed.
NCT04534699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04534699 about?
NCT04534699 is a clinical study titled "Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment". This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of KBP-5074.
What is the current status of trial NCT04534699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-08-27. Estimated completion is 2020-11-19.
What interventions are being tested in trial NCT04534699?
The interventions under investigation include: KBP-5074 (DRUG).
Who is sponsoring clinical trial NCT04534699?
This trial is sponsored by KBP Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.